Ziel/Aim Pridopidine is an investigational drug that was designed as dopamine stabilizer to treat motor symptoms in HD. As shown precinically, Pridopidine has much higher affinity to S1Rs as compared to D2/D3 Rs. S1R activation mediates neuroprotection and mental enhancement. To clarify the mechanism of action of Pridopidine and observed clinical outcomes in prior clinical trials, we quantified, using S1R-specific (-)-F-18-Fluspidine and D2/D3 R-specific F-18-Fallypidrefe PET, the S1R occupancy (S1RO) and D2/D3R occupancy (D2/D3RO) by Pridopidine at previously used clinical doses in HV and HD.
Ziel/Aim Pridopidine is under development as a drug to treat HD. Its effect is mainly mediated via sigma-1 receptor (S1 R) interaction. Little is known so far about how this interaction affects other brain processes in vivo. It was, thus, the aim of this study to investigate this feature by hybrid PET/MRI.
O. Voges合作论文数4M. Bronzel合作论文数4D. Marsteller合作论文数4JM Savola合作论文数4M. Geva合作论文数4Zientek Franziska合作论文数4Michael Rullmann合作论文数Leipzig Research Centre for Civilization Diseases, University of Leipzig4
Bernhard Sattler合作论文数University of Leipzig4
Henryk Barthel合作论文数Klinik und Poliklinik für Nuklearmedizin, University of Leipzig4
Swen Hesse合作论文数Department of Nuclear Medicine, University of Leipzig4Marianne Patt合作论文数Leipzig University4
Michael Hayden合作论文数Department of Medical Genetics, Faculty of Medicine, University of British Columbia3Georg Becker合作论文数Department für Nuklearmedizin, Leipzig University3PM Meyer合作论文数2A. Kluge合作论文数2
Mark Gordon合作论文数2Igor D. Grachev合作论文数2GA Becker合作论文数1
Philipp Valentin Meyer合作论文数Dept. of Nuclear Medicine, University of Leipzig1
